Strong Momentum Drives Venus Remedies to New Heights
On 21 Nov 2025, Venus Remedies recorded an intraday peak of Rs.724.95, marking its highest price level in over a year and setting an all-time high for the stock. This price point represents a significant advance from its 52-week low of Rs.272.20, illustrating a substantial appreciation in value over the past twelve months. The stock has demonstrated a consistent upward trajectory, gaining for three consecutive days and delivering a cumulative return of 27.45% during this period.
The stock’s performance today outpaced its sector peers, outperforming the Pharmaceuticals & Biotechnology sector by 2.48%. This relative strength is further supported by Venus Remedies trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained positive momentum across multiple timeframes.
Market Context and Sector Comparison
While Venus Remedies has surged ahead, the broader market has exhibited more subdued movement. The Sensex opened lower at 85,347.40, down 285.28 points or 0.33%, and was trading at 85,420.15 at the time of reporting, representing a 0.25% decline. Despite this, the Sensex remains close to its own 52-week high of 85,801.70, just 0.45% away, and is trading above its 50-day and 200-day moving averages, indicating an overall bullish trend in the market.
In comparison, Venus Remedies’ one-year performance stands out markedly, with a return of 136.72%, significantly exceeding the Sensex’s 10.71% gain over the same period. This divergence highlights the stock’s exceptional growth relative to the broader market benchmark.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Financial Metrics Underpinning the Rally
Venus Remedies’ recent financial disclosures provide insight into the factors supporting its stock performance. The company reported a net profit after tax (PAT) of Rs.20.13 crores for the latest quarter, reflecting a growth of 473.5% compared to previous periods. This robust profit expansion has been accompanied by four consecutive quarters of positive results, signalling consistent operational strength.
Additional financial ratios reinforce the company’s solid fundamentals. The return on capital employed (ROCE) for the half-year period reached 13.99%, its highest level, while the inventory turnover ratio stood at 6.58 times, indicating efficient management of stock levels. The return on equity (ROE) is reported at 10.5%, complemented by a price-to-book value ratio of 1.6, suggesting an attractive valuation relative to peers.
Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which points to a conservative capital structure and limited reliance on external borrowings. This financial prudence may contribute to the confidence reflected in the stock’s upward movement.
Long-Term and Recent Performance Trends
Over the past year, Venus Remedies has generated returns of 136.26%, with profits rising by 183%. The company’s price-to-earnings-to-growth (PEG) ratio stands at 0.1, indicating that the stock’s price growth is supported by earnings expansion. Furthermore, the stock has outperformed the BSE500 index over the last three years, one year, and three months, demonstrating sustained market-beating performance.
These metrics collectively illustrate a company that has delivered strong financial results and market returns, contributing to the stock’s recent milestone of reaching a new 52-week high.
Want to dive deeper on Venus Remedies ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Considerations on Market Participation
Despite the company’s size and strong financial profile, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund participation may reflect a cautious stance or differing assessment of the stock’s valuation or business prospects. Such dynamics are noteworthy given that domestic mutual funds often conduct detailed research and hold significant positions in companies they favour.
Nonetheless, Venus Remedies’ stock has demonstrated resilience and strength in the market, as evidenced by its recent price action and financial results.
Summary
Venus Remedies’ achievement of a new 52-week high at Rs.724.95 marks a significant milestone in its market journey. Supported by strong quarterly profits, efficient operational metrics, and a conservative capital structure, the stock’s momentum has outpaced both its sector and broader market indices. While the broader market shows cautious optimism, Venus Remedies continues to exhibit robust performance, reflecting its position within the Pharmaceuticals & Biotechnology sector.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
